---
document_datetime: 2024-10-30 11:57:38
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/delstrigo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: delstrigo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.3553255
conversion_datetime: 2025-12-28 20:15:13.26984
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Delstrigo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                       |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------|
| WS/2706              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Severe cutaneous adverse | 05/09/2024                          |                                             | SmPC and PL                      | For more information, please refer to the Summary of Product Characteristics. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | (SCARs) and to add \"toxic epidermal necrolysis (TEN)\" to the list of adverse drug reactions (ADRs) with frequency not known, based on clinical trials, literature and post-marketing safety data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to bring the PI in line with the latest QRD template version 10.4. and to implement editorial changes to the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | reactions   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IA/0038 | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                        | 20/11/2023 | n/a |             |
|         | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                        | 19/10/2023 | n/a | IB/0037/G   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/2553/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where   | 28/09/2023   | n/a        |                     |                                                                                                                   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------------|-------------------------------------------------------------------------------------------------------------------|
| R/0034      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 26/04/2023   | 23/06/2023 | SmPC, Labelling and | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     | PL          | Delstrigo in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0035             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                      | 15/05/2023 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| PSUSA/10731 /202208 | Periodic Safety Update EU Single assessment - doravirine / lamivudine / tenofovir disoproxil                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/03/2023 | n/a |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0033             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                       | 13/12/2022 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IG/1535             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 10/10/2022 |     | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| WS/2249             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.1 of SmPC based on two non- clinical studies (Study PD011: Assessment of in vitro antiviral activity against HIV-1 Resistant mutant, Y318F, alone and in combination with 12 other NNRTI mutants and Study PD012: In vitro antiviral activity of doravirine (MK-1439) Against a panel of viruses bearing NNRTI resistance-associated Mutations). In addition, the MAH took the | 14/07/2022 |     | SmPC and PL | Based on two non-clinical studies, Section 5.1 of the SmPC has been updated as follows: SmPC new text: Doravirine-resistant strains were selected in cell culture starting from wild-type HIV 1 of different origins and subtypes, as well as NNRTI-resistant HIV 1. Observed emergent amino acid substitutions in RT included: V106A, V106M, V106I, V108I, F227L, F227C, F227I, F227V, H221Y, M230I, L234I, P236L, and Y318F. The V106A, V106M, V108I, H221Y, F227C, M230I, P236L, and Y318F substitutions conferred 3.4-fold to 70-fold reductions in susceptibility to doravirine. Y318F in combination with |

<div style=\"page-break-after: always\"></div>

|                     | opportunity to implement editorial changes in the SmPC and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                           |            |            |                       | V106A, V106M, V108I, and F227C conferred greater decreases in susceptibility to doravirine than Y318F alone, which conferred a 10-fold reduction in susceptibility to doravirine. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1514             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                               | 21/06/2022 | n/a        |                       |                                                                                                                                                                                                                                                                   |
| PSUSA/10731 /202108 | Periodic Safety Update EU Single assessment - doravirine / lamivudine / tenofovir disoproxil                                                                                                                                                                                                                                                                                                               | 07/04/2022 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                 |
| IG/1497             | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS                                                                                                                                                                                         | 28/03/2022 | n/a        |                       |                                                                                                                                                                                                                                                                   |
| WS/2065             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Extension of indication to include the new indication to the paediatric population weighing at least 35 kgs for PIFELTRO and DELSTRIGO. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3 | 24/02/2022 | 28/03/2022 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Delstrigo-H-C- 004746/WS2065/0026' and 'Pifeltro-H-C- 004747/WS2065/0019'.                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | of the RMP for each product have also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial corrections and to update the list of local representatives in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                  |            |            |    |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| N/0025              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                             | 13/07/2021 | 28/03/2022 | PL |                                   |
| PSUSA/10731 /202008 | Periodic Safety Update EU Single assessment - doravirine / lamivudine / tenofovir disoproxil                                                                                                                                                                                                                                                                                                                 | 09/04/2021 | n/a        |    | PRAC Recommendation - maintenance |
| IG/1352             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                             | 11/02/2021 | n/a        |    |                                   |
| WS/1983/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other | 21/01/2021 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0023/G           | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.e.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supportive data | 14/12/2020 | n/a |                                   |
| PSUSA/10731 /202002 | Periodic Safety Update EU Single assessment - doravirine / lamivudine / tenofovir disoproxil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 01/10/2020 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0020           | B.II.g.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supporting data                                                                                                                                                                            | 18/08/2020   | n/a        |      |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-----------------------------------|
| IB/0019             | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                             | 23/06/2020   | 17/06/2021 | SmPC |                                   |
| IB/0017             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                     | 15/05/2020   | n/a        |      |                                   |
| IA/0016/G           | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier | 25/03/2020   | n/a        |      |                                   |
| PSUSA/10731 /201908 | Periodic Safety Update EU Single assessment - doravirine / lamivudine / tenofovir disoproxil                                                                                                                                                                                                               | 12/03/2020   | n/a        |      | PRAC Recommendation - maintenance |
| IA/0015             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                | 06/03/2020   | n/a        |      |                                   |

<div style=\"page-break-after: always\"></div>

| II/0012/G           | This was an application for a group of variations. B.I.e.2 - Introduction of a post approval change management protocol related to the AS B.I.e.3 - Deletion of an approved change management protocol related to the AS                                                                                                                                                                                                    | 05/03/2020   | n/a        |                              |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------------|-----------------------------------|
| IB/0014/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data | 07/02/2020   | n/a        |                              |                                   |
| II/0013/G           | This was an application for a group of variations. B.I.e.2 - Introduction of a post approval change management protocol related to the AS B.I.e.3 - Deletion of an approved change management protocol related to the AS                                                                                                                                                                                                    | 30/01/2020   | n/a        |                              |                                   |
| IB/0010             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                              | 13/12/2019   | 27/01/2020 | SmPC, Annex II and Labelling |                                   |
| PSUSA/10731 /201902 | Periodic Safety Update EU Single assessment - doravirine / lamivudine / tenofovir disoproxil                                                                                                                                                                                                                                                                                                                                | 03/10/2019   | n/a        |                              | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0008   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 05/09/2019   | 27/01/2020   | SmPC and PL   |                                                                                                                                                                                                                                                                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0009   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 20/08/2019   | n/a          |               |                                                                                                                                                                                                                                                                                   |
| IG/1108   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/05/2019   | n/a          |               |                                                                                                                                                                                                                                                                                   |
| II/0003   | Update of section 5.1 of the SmPC in order to reflect the week-96 results from studies P021, a phase 3 multicenter, double-blind, randomized active comparator-controlled clinical trial to evaluate the safety and efficacy of doravirine/ /lamivudine/ tenofovir disoproxil fumarate once daily compared with efavirenz/emtricitabine/tenofovir disoproxil fumarate once daily in treatment-naïve HIV-1 infected patients, as well as the study P018, a phase 3 multicenter, double-blind, randomized, active- comparator-controlled trial to evaluate the safety, efficacy, and pharmacokinetics of doravirine compared with ritonavir-boosted darunavir, each given in combination with emtricitabine/ tenofovir disoproxil fumarate or abacavir/lamivudine, in treatment-naïve HIV-1 infected patients. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 26/04/2019   | 27/01/2020   | SmPC          | No new safety findings are reported as a result of the week-96 CSRs of studies P018 and P021. However, section 5.1 of the SmPC has been updated to include resistance data up to week 96 in protocol defined virologic failure population or at early discontinuation population. |

<div style=\"page-break-after: always\"></div>

|         | of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0001 | Update of sections 4.8 and 5.1 of the SmPC in order to update the efficacy and safety information based on the results from the clinical study P024, a phase III multicenter, open-Label, randomized study to evaluate a switch to doravirine/lamivudine/tenofovir disproxil in virologically suppressed pateints. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity implement editorial changes in the SmPC and Package Leaflet, as well as to update the contact details of the local representative in Portugal in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 28/02/2019 | 27/01/2020 | SmPC and PL | The efficacy of switching from a baseline regimen consisting of two nucleoside reverse transcriptase inhibitors in combination with a ritonavir- or cobicistat-boosted PI, or cobicistat-boosted elvitegravir, or an NNRTI to Delstrigo was evaluated in a randomized, open-label trial (DRIVE- SHIFT), in virologically-suppressed HIV-1 infected adults. In the DRIVE-SHIFT trial, an immediate switch to Delstrigo was demonstrated to be non-inferior at Week 48 compared to continuation of the baseline regimen at Week 24 as assessed by the proportion of subjects with HIV-1 RNA < 40 copies/mL. Consistent results were seen for the comparison at Study Week 24 in each treatment group. Sections 5.1 of the SmPCs (Delstrigo, Pifeltro) have been updated with this data. The safety evaluation from this switch study did not reveal any new issues as compared to the safety findings in the prior pivotal studies. However, section 4.8 of the SmPC has been updated to include revised adverse reaction based on the Summary of Product Characteristics of 3TC and/or TDF. |
| IA/0004 | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/02/2019 | 27/01/2020 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0002 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 31/01/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |